Xencor, Inc.
General ticker "XNCR" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $885.6M (TTM average)
Xencor, Inc. follows the US Stock Market performance with the rate: 45.0%.
Estimated limits based on current volatility of 2.9%: low 11.43$, high 12.12$
Factors to consider:
- Total employees count: 250 (-10.7%) as of 2024
- Top business risk factors: Operational and conduct risks, Regulatory and compliance, Cybersecurity threats, Third-party risks, Clinical trial uncertainties
- Price in estimated range
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [11.74$, 24.87$]
- 2026-12-31 to 2027-12-31 estimated range: [10.55$, 22.78$]
Financial Metrics affecting the XNCR estimates:
- Negative: with PPE of -12.5 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -11.77 <= 0.01
- Positive: Shareholder equity ratio, % of 72.60 > 64.29
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: Interest expense per share per price, % of 2.78 <= 3.28
- Negative: negative Net income
Short-term XNCR quotes
Long-term XNCR plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $174.62MM | $110.49MM | $125.58MM |
| Operating Expenses | $306.98MM | $288.90MM | $303.08MM |
| Operating Income | $-132.36MM | $-178.41MM | $-177.50MM |
| Non-Operating Income | $12.73MM | $-56.52MM | $88.08MM |
| Interest Expense | $6.18MM | $36.64MM | $31.93MM |
| R&D Expense | $253.60MM | $227.69MM | $239.43MM |
| Income(Loss) | $-119.63MM | $-234.92MM | $-89.42MM |
| Taxes | $13.66MM | $1.62MM | $2.50MM |
| Profit(Loss)* | $-133.13MM | $-232.62MM | $-91.92MM |
| Stockholders Equity | $661.75MM | $677.61MM | $635.59MM |
| Assets | $965.13MM | $951.95MM | $875.50MM |
| Operating Cash Flow | $-77.93MM | $-202.19MM | $-135.12MM |
| Capital expenditure | $18.45MM | $6.10MM | $3.15MM |
| Investing Cash Flow | $-111.06MM | $-7.87MM | $139.99MM |
| Financing Cash Flow | $189.22MM | $197.15MM | $8.23MM |
| Earnings Per Share** | $-2.20 | $-3.58 | $-1.24 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.